cAd3-EBO: Phase I data

An open-label, U.S. Phase I trial in 20 healthy adult volunteers showed that 2*1010 and 2*1011 particle-unit doses of intramuscular cAd3-EBO were well tolerated and induced glycoprotein-specific antib...